Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose

Read more at globenewswire.com